The hilarious thing you can't see @Doug Diamond, is he now calls me a fool and victim (and you ignorant) for posting that! He is such a clueless baiter. The victim stuff, I think emerged (who can imagine his logic) because I tried to discuss above that versus the 10% untreated survival rate, or extrapolated Ruxolitinib (Jakafi) 2 year survival rates to 30%, CYP might have extended the lives of 4-6 people of 15 who might otherwise be dead.
It is ironic that his insults forced me to illustrate the ridiculousness of his CYP valuation arguments, with a more mercantile orientated ratio, illustrating the disparity of CYP, with its fully funded phase III trial in place, trading at a ridiculous 1.3 times cash on hand, vs MSB's 11.3 times. Lets put that in bold again to annoy him and provide Hot Copper readers with something actually useful, CYP, that has achieved comparable results to MSB in its admittedly early phase GVHD trial (60% 2-year SRR in adults vs 51% in children), and has, unlike MSB a fully funded phase III trial, trades at 1.3 x cash on hand, whilst MSB trades at 11.3 x cash on hand.
Both MSB (who I remain invested in despite its high multiples by any traditional pre-profit measure) and CYP are hopefully and nobly soon likely to help a hell of a lot of desperate and dying patients with unmet medical needs. Pledge's insults to me are water off a duck's back compared to their struggles.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)